Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders Publisher Pubmed



Oertel FC1, 2, 3 ; Zimmermann HG1, 2, 4 ; Motamedi S1, 2 ; Bereuter C1, 2 ; Manthey LM1, 2 ; Ashtari F5 ; Kafieh R6 ; Dehghani A7 ; Pourazizi M7 ; Pandit L8 ; Dcunha A8 ; Aktas O9 ; Albrecht P9, 10 ; Ringelstein M9, 11 Show All Authors
Authors
  1. Oertel FC1, 2, 3
  2. Zimmermann HG1, 2, 4
  3. Motamedi S1, 2
  4. Bereuter C1, 2
  5. Manthey LM1, 2
  6. Ashtari F5
  7. Kafieh R6
  8. Dehghani A7
  9. Pourazizi M7
  10. Pandit L8
  11. Dcunha A8
  12. Aktas O9
  13. Albrecht P9, 10
  14. Ringelstein M9, 11
  15. Martinezlapiscina EH12
  16. Sanchez Dalmau BF12
  17. Villoslada P12
  18. Asgari N13, 14
  19. Marignier R15
  20. Cobocalvo A15, 16
  21. Leocani L17
  22. Pisa M17
  23. Radaelli M17
  24. Palace J18
  25. Rocafernandez A18
  26. Leite MIS18
  27. Sharma S19
  28. De Seze J20
  29. Senger T20
  30. Yeaman MR21, 22
  31. Smith TJ23, 24
  32. Cook LJ25
  33. Brandt AU1, 2
  34. Paul F1, 2, 3
Show Affiliations
Authors Affiliations
  1. 1. Experimental and Clinical Research Center, Max Delbruck Center for Molecular Medicine, Charite-Universitatsmedizin Berlin, Berlin, Germany
  2. 2. Neuroscience Clinical Research Center, Charite-Universitatsmedizin Berlin, Freie Universitat Berlin and Humboldt, Universitat zu Berlin, Berlin, Germany
  3. 3. Department of Neurology, Charite-Universitatsmedizin Berlin, Freie Universitat Berlin, Humboldt-Universitat zu Berlin, Berlin, Germany
  4. 4. Einstein Center Digital Future, Berlin, Germany
  5. 5. Kashani MS Center, Isfahan University of Medical Sciences, Iran
  6. 6. School of Advanced Technologies in Medicine and Medical Image, Signal Processing Research Center, Iran
  7. 7. Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Iran
  8. 8. Department of Neurology, KS Hegde Medical Academy, Nitte University, Mangalore, India
  9. 9. Department of Neurology, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany
  10. 10. Department of Neurlogy, Kliniken Maria Hilf Monchengladbach, Germany
  11. 11. Centre for Neurology and Neuropsychiatry, Landschaftsverband Rheinland-Klinikum Dusseldorf, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany
  12. 12. Hospital Clinic of Barcelona-Institut d'Investigacions, Biomediques August Pi Sunyer (IDIBAPS), Barcelona, Spain
  13. 13. Departments of Neurology, Slagelse Hospitals Denmark, Institute of Regional Health Research, Odense, Denmark
  14. 14. Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
  15. 15. Service de Neurologie, Sclerose en Plaques Pathologies de la Myeline et Neuro-inflammation, Centre de Reference des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Hopital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France
  16. 16. Centre d'Esclerosi Multiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Spain
  17. 17. Experimental Neurophysiology Unit, Institute of Experimental Neurology (INSPE), Scientific Institute San Raffaele, University Vita-Salute San Raffaele, Milan, Italy
  18. 18. Department of Neurology, Oxford University Hospitals, National Health Service Trust, United Kingdom
  19. 19. Department of Ophthalmology, Oxford University Hospitals, National Health Service Trust, United Kingdom
  20. 20. Neurology Service, University Hospital of Strasbourg, France
  21. 21. Department of Medicine, Divisions of Molecular Medicine and Infectious Diseases, Harbor-University of California at Los Angeles (UCLA), Medical Center, Lundquist Institute for Biomedical Innovation, Torrance, United States
  22. 22. Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, United States
  23. 23. Departments of Ophthalmology and Visual Sciences, Kellogg Eye Center, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, United States
  24. 24. Division of Metabolism Endocrine and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, United States
  25. 25. Department of Pediatrics, University of Utah, United States

Source: Neurology: Neuroimmunology and NeuroInflammation Published:2024


Abstract

Background and ObjectivesTo systematically describe the clinical picture of double-Antibody seronegative neuromyelitis optica spectrum disorders (DN-NMOSD) with specific emphasis on retinal involvement.MethodsCross-sectional data of 25 people with DN-NMOSD (48 eyes) with and without a history of optic neuritis (ON) were included in this study along with data from 25 people with aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD, 46 eyes) and from 25 healthy controls (HCs, 49 eyes) for comparison. All groups were matched for age and sex and included from the collaborative retrospective study of retinal optical coherence tomography (OCT) in neuromyelitis optica (CROCTINO). Participants underwent OCT with central postprocessing and local neurologic examination and antibody testing. Retinal neurodegeneration was quantified as peripapillary retinal nerve fiber layer thickness (pRNFL) and combined ganglion cell and inner plexiform layer thickness (GCIPL).ResultsThis DN-NMOSD cohort had a history of [median (inter-quartile range)] 6 (5; 9) attacks within their 5 ± 4 years since onset. Myelitis and ON were the most common attack types. In DN-NMOSD eyes after ON, pRNFL (p < 0.001) and GCIPL (p = 0.023) were thinner compared with eyes of HCs. Even after only one ON episode, DN-NMOSD eyes already had considerable neuroaxonal loss compared with HCs. In DN-NMOSD eyes without a history of ON, pRNFL (p = 0.027) and GCIPL (p = 0.022) were also reduced compared with eyes of HCs. However, there was no difference in pRNFL and GCIPL between DN-NMOSD and AQP4-NMOSD for the whole group and for subsets with a history of ON and without a history of ON-as well as between variances of retinal layer thicknesses.DiscussionDN-NMOSD is characterized by severe retinal damage after ON and attack-independent retinal neurodegeneration. Most of the damage occurs during the first ON episode, which highlights the need for better diagnostic markers in DN-NMOSD to facilitate an earlier diagnosis as well as for effective and early treatments. In this study, people with DN-NMOSD presented with homogeneous clinical and imaging findings potentially suggesting a common retinal pathology in these patients. © American Academy of Neurology.
Other Related Docs
17. Frequency of Comorbidities in Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis and Related Disorders (2021)
18. Vitamin D Level in Iranian Patients With Neuromyelitis Optica, Journal of Isfahan Medical School (2021)
23. Frequency of Diencephalic Syndrome in Nmosd, Acta Neurologica Belgica (2022)
29. Whole Spinal Transverse Myelitis in Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis and Related Disorders (2024)